Journal of neuroradiology = Journal de neuroradiologie · 2026
Glymphatic system dysfunction in gliomas: A systematic review and meta-analysis of DTI-ALPS index.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dehaghi Fatemeh Taheri, Nasab Amirsaman Soleimani, Arabi Narges, Abedi Iraj
Аннотация
BACKGROUND: The glymphatic system's role in brain waste clearance is increasingly recognized in glioma pathophysiology. This study synthesizes evidence on DTI-ALPS index variations across glioma grades, molecular subtypes, and clinical outcomes to evaluate its diagnostic and prognostic utility.
METHODS: Following PRISMA 2020, major databases were searched up to December 20, 2025, for studies of adults with histologically confirmed gliomas who underwent DTI-ALPS assessment. Risk of bias was evaluated using ROBINS-E, and reporting quality using the STROBE checklist. Random-effects meta-analyses examined ALPS differences for six different outcome comparisons.
RESULTS: Fourteen studies were included. ROBINS-E revealed very high risk of bias in 14% of studies and some concerns in 64%; mean STROBE compliance was 92.2%. High-grade gliomas exhibited lower ALPS indices than low-grade tumors (MD=0.14, 95% CI: 0.11-0.16; I2=0%). IDH wild-type gliomas showed lower ALPS indices than IDH-mutant tumors (MD=0.14, 95% CI: 0.10-0.18; I2=38%). Multivariate Cox regression demonstrated that lower ALPS index is associated with worse overall survival (HR=0.73, 95% CI: 0.49-1.10; I2=57%).
CONCLUSION: DTI-ALPS index reliably detects glymphatic dysfunction in gliomas and provides prognostic information, supporting its use as a non-invasive biomarker for glioma assessment. However, methodological standardization and prospective multicenter studies are needed for clinical integration.
METHODS: Following PRISMA 2020, major databases were searched up to December 20, 2025, for studies of adults with histologically confirmed gliomas who underwent DTI-ALPS assessment. Risk of bias was evaluated using ROBINS-E, and reporting quality using the STROBE checklist. Random-effects meta-analyses examined ALPS differences for six different outcome comparisons.
RESULTS: Fourteen studies were included. ROBINS-E revealed very high risk of bias in 14% of studies and some concerns in 64%; mean STROBE compliance was 92.2%. High-grade gliomas exhibited lower ALPS indices than low-grade tumors (MD=0.14, 95% CI: 0.11-0.16; I2=0%). IDH wild-type gliomas showed lower ALPS indices than IDH-mutant tumors (MD=0.14, 95% CI: 0.10-0.18; I2=38%). Multivariate Cox regression demonstrated that lower ALPS index is associated with worse overall survival (HR=0.73, 95% CI: 0.49-1.10; I2=57%).
CONCLUSION: DTI-ALPS index reliably detects glymphatic dysfunction in gliomas and provides prognostic information, supporting its use as a non-invasive biomarker for glioma assessment. However, methodological standardization and prospective multicenter studies are needed for clinical integration.